Multi-channel program using a virtual tribal health educator to boost colorectal cancer screening for American Indian adults in Oklahoma.
Official title: Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
Run by University of Oklahoma · NCT07254910 · Data updated 2026-11-12
This project will try a virtual tribal community health educator delivered by social media and clinic text messages to see if it increases colorectal cancer screening among American Indian adults aged 45–75 in the IHS Clinton Service Unit.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 75 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Status | Recruiting |
| Started | August 30, 2026 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT07254910 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 45–75 who live in the IHS Clinton Service Unit area, self-identify as American Indian (or have a CDIB), read English at about a sixth-grade level, and are not current with CRC screening are ideal candidates.
✕Probably not a fit
People who are already up-to-date with CRC screening, live outside the Clinton Service Unit catchment, cannot read English, or prefer in-person tribal health educator support may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program partners with Tribal Nations, Area Indian Health Boards, and the IHS Clinton Service Unit to co-develop a virtual tribal community health educator (v-TCHE) and testimonial video as part of a multi-channel outreach effort. The intervention will be delivered via social media adverts and direct clinic SMS links and will emphasize culturally concordant messaging and access to home stool (FIT) kits. Investigators will measure the reach, engagement, and feasibility of the v-TCHE delivery across both channels and track screening-related outcomes. The work is conducted from the TSET Health Promotion Research Center with collaborative input from tribal partners to ensure cultural fit.
Why it matters
Potential benefit: If successful, this approach could increase FIT uptake and overall colorectal cancer screening in American Indian communities by offering a scalable, culturally tailored outreach method.
How similar studies have gone: Community health educator outreach and FIT programs have improved screening in similar populations, but using a photorealistic virtual TCHE delivered via social media and clinic text is a novel and largely untested approach in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 45-75 Live within IHS Clinton Service Unit catchment area Fluent in English and read at or above 6th grade level Self report as American Indian or have CDIB Exclusion Criteria: * Self report up to date with CRC screening FIT within 1 year
Where it's running
-
TSET Health Promotion Research Center
Oklahoma City, Oklahoma, United States Recruiting
Study contacts
- Principal investigator: Jordan Neil, PhD — University of Oklahoma
- Study coordinator: Jordan Neil, PhD
- Email: jordan-neil@ou.edu
- Phone: (405) 271-5046
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
HDM2017 combination therapy in advanced colorectal cancer
A small and mid-size study tests HDM2017 with standard chemotherapy and targeted drugs to see if it’s safe and may help people with unresectable or metastatic colorectal cancer.
-
Retlirafusp alfa with bevacizumab and chemotherapy (with or without short radiotherapy) for colorectal cancer liver metastases
This study tests whether adding retlirafusp alfa to bevacizumab and chemotherapy, with or without short-course radiotherapy, can help patients with advanced colorectal cancer that has spread to the liver.
-
Gixam device to spot advanced or non-advanced colon cancer in people 45–84 who had a negative FIT
This trial tests whether the Gixam device can find pre-cancer or cancer in adults 45–84 who had a negative FIT result.
-
SHR-1701 with short-course radiotherapy and CAPOX before surgery for locally advanced rectal cancer
This will test whether adding the drug SHR-1701 to short-course radiotherapy plus CAPOX before surgery helps people with locally advanced rectal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.